Clinical trials: Hyperlipoproteinemia Type II
Familial Hypercholesterolemia
Familial Hypercolerstremia as Risk Factor in Stemi Patient Who Underwent Ppci
Famulial hypercolerstremia as risk factor
- Trial name
- NCT03900169
- Testing
- Genetic
- Where
- Egypt
- Volunteers
- 2 people
- Sponsor
- Assiut University
Heterozygous Familial Hypercholesterolemia
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.
- Trial name
- STEATO-FH (NCT06634160)
- Testing
- Fibroscan, Sample collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Nantes University Hospital
Heterozygous Familial Hypercholesterolemia
Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.
- Trial name
- HAUSER-RCT (NCT02392559)
- Testing
- Evolocumab
- Where
- 66 sites in United States, Australia and 24 more
- Volunteers
- 158 people
- Sponsor
- Amgen
Familial Hypercholesterolemia
Cascade Genetic Testing of Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is a frequent genetic disorder (1/200) associated with an increased risk of early-onset myocardial infarction.
- Trial name
- CATCH (NCT04419090)
- Testing
- web-based centralized service and message
- Where
- Switzerland
- Volunteers
- 379 people
- Sponsor
- Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Lysosomal Acid Lipase Deficiency
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)
Familial Hypercholesterolemia (FH) is a monogenic autosomal dominant disease also known as Autosomal Dominant Hypercholesterolemia - ADH) that leads to dramatically increased levels of Low Density Lipoprotein (LDL) and total…
- Trial name
- NCT03984149
- Testing
- Observational study
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
Primary Hypercholesterolemia or Mixed Hyperlipidemia
QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy.
- Trial name
- NCT07444086
- Testing
- QLC7401
- Volunteers
- 510 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hypercholesterolemia, Familial Hypercholesterolemia
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
The study will assess the safety and tolerability of Ezetimibe 10 mg+ Rosuvastatin 2.5 mg and Ezetimibe 10 mg+ Rosuvastatin 5.0 mg for up to 52 weeks in Japanese participants with hypercholesterolemia uncontrolled with…
- Trial name
- NCT02748057
- Testing
- Ezetimibe, Rosuvastatin
- Volunteers
- 135 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Familial
Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia
Patients with homozygous familial hypercholesterolemia has very high serum cholesterol levels despite receiving lipid lowering drugs (e.g. statins, etc).
- Trial name
- NCT00515307
- Testing
- Cellular transplantation
- Where
- Iran
- Volunteers
- 1 people
- Sponsor
- University of Tehran
Familial Hypercholesterolemia, Lipid Disorder
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Familial hypercholesterolemia (FH) is the most frequent genetic lipoprotein disorder associated with premature CAD. In Canada, the burden of disease is estimated to be approximately 83,500 patients.
- Trial name
- FHCanada (NCT02009345)
- Where
- Canada
- Volunteers
- 6,000 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Prediabetes, Obesity
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk.
- Trial name
- NCT02104739
- Testing
- Exenatide, Saxagliptin, Exenatide extended-release (ER)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, Metastatic Cancer
- Trial name
- NCT04862260
- Testing
- Cholesterol metabolism disruption
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- CHU de Quebec-Universite Laval
Hyperlipidemia, Insulin Resistance
Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Background: There is general agreement that statin-treatment of patients to lower plasma cholesterol levels can increase the incidence of type 2 diabetes mellitus (T2D) in some individuals1-5.
- Conditions
- Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
- Trial name
- NCT02437084
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Stanford University
Familial Hypercholesterolemia
Coronary and Heart Effects of Early Treatment in Familial Hypercholesterolemia
This study evaluates plaque burden and characteristics in early-treated FH patients compared to late-treated FH patients and healthy individuals.
- Trial name
- CHEETAH (NCT05352386)
- Testing
- Coronary computed tomography angiography (CCTA)
- Where
- Netherlands
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hyperlipidemia; Mixed
Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study
This randomized controlled pharmacokinetic based study will be carried out on patients with both sexes and various ages, plasma triglycerides levels, clinical health disorders and using different agents for treatment of their…
- Trial name
- NCT05080140
- Testing
- Ezetimibe 10mg
- Where
- Egypt
- Volunteers
- 3 people
- Sponsor
- Misr University for Science and Technology
Hypercholesterolemia, Familial
Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®
Protein convertase subtilisin kexin type 9 (PCSK-9) inhibitors demonstrated efficacy in cholesterol reduction and in the prevention of cardiovascular events.
- Trial name
- NCT04313270
- Testing
- Evolocumab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Federico II University
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or…
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- NCT00477594
- Testing
- mipomersen sodium
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kastle Therapeutics, LLC
Dyslipidemias, Familial Hypercholesterolemia
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers
This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT05851066
- Testing
- VSA003, 0.9% NaCl
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Visirna Therapeutics HK Limited
Heterozygous Familial Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).
JS002 is a recombinant human anti-PCSK9 monoclonal antibody.The study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study in Chinese patients with heterozygous familial hypercholesterolemia…
- Trial name
- NCT05325203
- Testing
- Ongericimab
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Familial Hypercholesterolemia
Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
The primary objective of this study is to measure how LDL apheresis affects levels of inflammatory and cholesterol markers in human beings.
- Trial name
- INFLAME (NCT01138371)
- Testing
- LDL Apheresis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Familial Hypercholesterolemia
Effect of Omega-3 Fatty Acid on Endothelial Function
Background Familial hypercholesterolemia (FH) is an inherited disease in which the level of bad cholesterol (LDL-cholesterol) is increased, leading to an increase in coronary heart disease even if adequately treated with…
- Trial name
- NCT01813006
- Testing
- Omega-3
- Where
- Norway
- Volunteers
- 34 people
- Sponsor
- Nordlandssykehuset HF